Literature DB >> 18489014

The influence of transdermal nicotine on tobacco/nicotine abstinence and the effects of a concurrently administered cigarette in women and men.

Bethea A Kleykamp1, Janine M Jennings, Cynthia Sams, Michael F Weaver, Thomas Eissenberg.   

Abstract

Transdermal nicotine (TN) is an efficacious smoking cessation pharmacotherapy thought to work, in part, by attenuating the effects of tobacco/nicotine abstinence and the effects of concurrently smoked cigarettes. Clinical trials suggest that TN may be less efficacious for women. This study explored the possibility of TN-related gender differences in > or = 8 hour abstinent smokers (54 women, 70 men) who completed four within-subject, double-blind, placebo-controlled sessions corresponding to 0, 7, 14, and 21 mg TN. In each approximately 6.5-hr long session participants smoked an own-brand cigarette 4 hours after TN administration and physiological and subjective outcomes were examined throughout each session. Results revealed that TN suppressed some signs and symptoms of tobacco abstinence and attenuated some effects of smoking, and these effects were not dependent on gender. Women were more sensitive to the direct effects of nicotine (e.g., ratings of Nauseous) and, independent of TN dose, self-administered less nicotine when smoking and rated smoking as less rewarding. Thus, although this study does not shed light on clinical observations that TN is less effective for women, results suggest that TN might need to be combined with other interventions to supplement its effects on tobacco/nicotine abstinence and concurrent smoking.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489014     DOI: 10.1037/1064-1297.16.2.99

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  21 in total

1.  Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure and subjective effects.

Authors:  Caroline O Cobb; Alan Shihadeh; Michael F Weaver; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2010-12-02       Impact factor: 4.244

2.  A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects.

Authors:  Andrea R Vansickel; Caroline O Cobb; Michael F Weaver; Thomas E Eissenberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

3.  Electronic cigarettes: effective nicotine delivery after acute administration.

Authors:  Andrea Rae Vansickel; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2012-02-06       Impact factor: 4.244

4.  CO exposure, puff topography, and subjective effects in waterpipe tobacco smokers.

Authors:  Wasim Maziak; Samer Rastam; Iman Ibrahim; Kenneth D Ward; Alan Shihadeh; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2009-05-06       Impact factor: 4.244

Review 5.  History repeats itself: Role of characterizing flavors on nicotine use and abuse.

Authors:  Theresa Patten; Mariella De Biasi
Journal:  Neuropharmacology       Date:  2020-06-01       Impact factor: 5.250

6.  Effects of varenicline and bupropion on cognitive processes among nicotine-deprived smokers.

Authors:  Rebecca L Ashare; Sherry A McKee
Journal:  Exp Clin Psychopharmacol       Date:  2011-09-26       Impact factor: 3.157

Review 7.  Consideration of sex in clinical trials of transdermal nicotine patch: a systematic review.

Authors:  Andrea H Weinberger; Philip H Smith; Mira Kaufman; Sherry A McKee
Journal:  Exp Clin Psychopharmacol       Date:  2014-08-18       Impact factor: 3.157

8.  Electronic cigarette effectiveness and abuse liability: predicting and regulating nicotine flux.

Authors:  Alan Shihadeh; Thomas Eissenberg
Journal:  Nicotine Tob Res       Date:  2014-09-01       Impact factor: 4.244

9.  Effects of transdermal nicotine and concurrent smoking on cognitive performance in tobacco-abstinent smokers.

Authors:  Bethea A Kleykamp; Janine M Jennings; Thomas Eissenberg
Journal:  Exp Clin Psychopharmacol       Date:  2011-02       Impact factor: 3.157

Review 10.  Abuse liability assessment of tobacco products including potential reduced exposure products.

Authors:  Lawrence P Carter; Maxine L Stitzer; Jack E Henningfield; Rich J O'Connor; K Michael Cummings; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.